Tristel results don’t convince markets

0 mins. to read
Tristel results don’t convince markets

AIM-listed infection control specialist Tristel (LON:TSTL) saw its share price drop by 8.39% to 426p (as of 15:30 BST) even as revenues rose by 21% during the year ended 30th June. Growth was driven by overseas markets, but since March there has been a drastic shift in product mix due to COVID and related changes in medical behaviour.

CEO Paul Swinney commented: “We are very pleased with our performance during a turbulent period. To maintain the momentum that has built over the past four months we need hospitals, especially in the UK, to return to pre-COVID-19 levels of patient throughput. Whilst we believe that hospitals will revert to more normal levels of activity, we cannot be certain as to timing.

“We also need hospitals to maintain the intensity of their cleaning and disinfection routines, searching for and selecting the best-performing disinfection technology, such as our chlorine dioxide-based products.

“We are cautiously optimistic for the Company’s prospects in this financial year and beyond“.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *